BMS Archive

Plant · Scientific monograph

Zingiber officinale

Ginger

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Inflammatory Pathways, Gastrointestinal Research, Pain Signaling Research

Research overview

Historical use

Zingiber officinale has been cultivated and used medicinally for over 3,000 years across Asia, the Middle East, and the Mediterranean. In Ayurveda it is known as 'Vishwabheshaj' (universal medicine) and applied for digestive disorders, nausea, arthritis, and respiratory ailments. Arabic and Greek physicians documented its carminative and diaphoretic properties. Traditional Chinese Medicine employs both fresh (Sheng Jiang) and dried (Gan Jiang) ginger for different clinical indications.

Modern research context

Ginger is among the most pharmacologically validated herbal medicines. The strongest clinical evidence supports antiemetic activity in pregnancy-related nausea and chemotherapy-induced nausea [6]. A 2026 triple-blind RCT in paediatric juvenile idiopathic arthritis (Bozorgvar et al.) demonstrated significant improvements in ACR-Pedi response criteria with ginger supplementation [5]. Ginger bioactives act as multi-target therapeutics across cardiovascular, inflammatory, neurological, and metabolic pathways [6]. Drug interaction potential is substantial: ginger inhibits 17 of 33 clinically relevant drug transporters in vitro through gingerol and shogaol components [2] and modulates multiple CYP450 isoforms [1, 3]. A documented tacrolimus-ginger interaction via CYP3A4/P-gp inhibition raises specific concerns in transplant recipients [4].

Adverse effects

Well-tolerated at culinary doses. At higher supplemental doses (>2–4 g/day): heartburn, GI discomfort, belching, and mild diarrhoea. Antiplatelet activity at doses >2 g/day. Contact dermatitis with topical application. Drug interaction risk escalates at supplemental doses.

Contraindications

Caution with anticoagulants (warfarin, direct oral anticoagulants) and antiplatelet drugs due to additive antiplatelet effects. Contraindicated at high supplemental doses in transplant patients on tacrolimus or cyclosporine due to CYP3A4/P-gp inhibition [4]. Pre-operative cessation recommended (≥7 days). Avoid high-dose supplements with narrow therapeutic index substrates of CYP1A2, CYP3A4, or CYP2C9 [1, 3].

Clinical and phytochemical data

Used part

Rhizome (fresh and dried)

Primary active compounds

  • 6-Gingerol

  • 8-Gingerol

  • 10-Gingerol

  • 6-Shogaol (dehydration product of 6-gingerol)

  • Paradol

  • Zingerone

  • β-Bisabolene (essential oil terpene)

Mechanism of action

Anti-inflammatory activity via dual inhibition of COX-1/COX-2 and 5-LOX enzymes, suppressing prostaglandin E2 and leukotriene B4 synthesis; concurrent inhibition of NF-κB and MAPK signalling cascades reduces pro-inflammatory cytokine production [6]. Antiemetic mechanism involves antagonism of 5-HT3 receptors in the GI tract and CNS, and modulation of NK1 receptors [6]. 6-Gingerol demonstrates anticonvulsant activity through selective modulation of voltage-gated sodium channels in preclinical seizure models [8]. Metabolic effects include PPAR-γ and AMPK activation, improving insulin sensitivity [7]. Ginger components inhibit 17 of 33 clinically relevant drug transporters including OATP1B1/1B3 (hepatic uptake), OCT2, OAT1/3, MATE1/2-K (renal), and P-gp (efflux) [2].

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — 6-Gingerol is rapidly absorbed following oral administration in animal models; peak plasma concentrations achieved within 0.5–1 hour. Absolute bioavailability is limited by rapid first-pass metabolism and conversion to shogaols and conjugated gingerol metabolites in the gut wall and liver [3, 6]. In vitro transporter inhibition studies demonstrate that both gingerols and shogaols interact with 17 of 33 clinically relevant transport proteins (Varga T et al., 2026), suggesting transporter-mediated absorption is a significant component of disposition [2].

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Gingerols and shogaols are highly lipophilic and distribute broadly to peripheral tissues including liver, kidney, brain, and gastrointestinal mucosa. Plasma protein binding is high (>90%) for gingerols [3]. Tissue distribution studies show preferential hepatic concentration, consistent with the site of principal CYP450-mediated metabolism [6].

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — 6-Gingerol undergoes rapid hepatic biotransformation via reduction to 6-gingerol alcohol followed by glucuronidation and sulfation (phase II). Oxidative metabolism via CYP3A4 and CYP1A2 generates hydroxylated metabolites. Gingerols and shogaols concurrently inhibit these CYP enzymes at supplemental concentrations, creating potential for auto-inhibition and drug interactions [1, 3]. Gut microbiota further metabolise gingerol to zingerone and simple phenolics.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Primary elimination is renal for phase II-conjugated gingerol metabolites (glucuronides, sulfates). Biliary excretion accounts for high-molecular-weight conjugates. Elimination half-life of 6-gingerol and primary metabolites estimated at 3–5 hours in rodent models [3].

Safety and interactions

Drug interactions

Ginger has well-characterised drug interaction potential through multiple mechanisms. An in vitro pharmacological study (Varga T et al., 2026) demonstrated inhibition of 17 of 33 clinically relevant uptake and efflux transporters — including hepatic (OATP1B1, OATP1B3) and renal (OCT2, OAT1/3, MATE1/2-K) transporters — by gingerols and shogaols; prolonged high-dose consumption may pose clinically significant transporter-mediated herb-drug interactions [2]. Modulation of CYP1A2, CYP3A4, and CYP2C9 affects metabolism of co-administered substrates including tacrolimus, cyclosporine, warfarin, and statins [1, 3]. Clinically documented tacrolimus-ginger interaction showed increased tacrolimus plasma concentrations through combined CYP3A4 and P-gp inhibition, with implications for therapeutic drug monitoring in transplant patients [4]. Additive antiplatelet effects with NSAIDs and anticoagulants at supplemental doses [6].

Toxicity

Acute oral LD50 for ginger extract >5 g/kg in rodents. GRAS status at food use levels (US FDA). Clinical trials at supplemental doses (1–4 g/day) demonstrate a favourable tolerability profile, including in paediatric RCTs [5]. No hepatotoxicity or haematological toxicity documented at standard doses; long-term safety data beyond the studied durations are limited.

Special precautions

Pregnancy

Culinary use has a long traditional food history and no teratogenicity has been demonstrated at culinary doses. For nausea of pregnancy, ginger (1–1.5 g/day) is a first-line non-pharmacological option with clinical trial support; doses >1.5 g/day should be avoided due to insufficient safety data at higher doses. Medicinal-dose supplementation should be discussed with a healthcare provider.

Lactation

Culinary use is accepted based on extensive traditional food history; culinary-level consumption is not expected to pose a significant risk, though controlled clinical safety data during lactation are limited. Avoid high-dose supplemental preparations.

Hepatic impairment

Use with caution. Extensive hepatic first-pass metabolism; CYP450 interactions are more pronounced with hepatic dysfunction. Avoid high-dose supplements.

Renal impairment

Transporter-mediated interactions at the kidney (OCT2, OAT1/3, MATE1/2-K) documented in vitro [2]; caution warranted when co-administered with renally cleared drugs at supplemental doses.

Sources and references

  1. [1] - Shanaida M et al., "Herbal Medicines and Drugs Interactions: Cytochrome P450 Responsibility.", Current Medicinal Chemistry, 2026, PMID: 41764614
  2. [2] - Varga T et al., "Ginger and Its Purified Major Components Inhibit Clinically Relevant Uptake and Efflux Transporters In Vitro.", Pharmaceutics, 2026, PMID: 41754892
  3. [3] - Husain I et al., "Ginger as a Modulator of Drug Metabolizing Enzymes and Transporters.", Journal of Dietary Supplements, 2026, PMID: 41457469
  4. [4] - Tolou-Ghamari Z., "Tacrolimus, Cytochrome P450, Interactions with Food Variables.", Current Drug Metabolism, 2025, PMID: 39757635
  5. [5] - Bozorgvar M et al., "Ginger Supplementation in Children with Oligoarticular Juvenile Idiopathic Arthritis: Triple-Blind Randomized Clinical Trial.", Avicenna Journal of Phytomedicine, 2026, PMID: 42153012
  6. [6] - Simeone P et al., "Ginger Bioactives as Multi-Target Therapeutics.", Nutrients, 2026, PMID: 41978129
  7. [7] - Kuzia N et al., "Antidiabetic and Anti-Inflammatory Potential of Zingiberaceae Plants.", Molecules, 2026, PMID: 41599361
  8. [8] - Nieoczym D et al., "Studies on the Anticonvulsant Potential of 6-Gingerol.", Frontiers in Pharmacology, 2026, PMID: 42110551

Additional source links

Continue browsing